A randomized multicenter clinical study of cefpodoxime proxetil tablets in treatment of acute bacterial infections in 158 patients

AIM: To evaluate the clinical efficacy and safety of domestic cefpodoxime proxetil tablets in the treatment of acute bacterial infections. METHODS: A randomized multicenter clinical study was conducted for comparing domestic cefpodoxime proxetil tablets with inported cefpodoxime proxetil tablets. Both were administered orally at a dose of 100 mg twice daily for 7 to 14 days. RESULTS: Altogether, 175 patients were enrolled in the study. Among them 158 patients were eligible for clinical efficacy analysis inclnding 77 in domestic cefpodoxime proxetil proxetil group, 81 in control group. The cure rates and effective rates were 70 % and 92 %in domestic cefpodoxime proxetil group; and 79 % and 94 %in control group, respectively. The bacterial eradication rates were 98 % and 98 %, respectively. There were no statistically significant difference between the two treatment groups. Adverse reactions were observed for 9 % and 2 % of patients in the two groups, dominated by thirsty, nausea, abdominal discomfort and elevated transaminases. CONCLUSION: Domestic cefpodoxime proxetil tablet is effective and safe for the treatment of acute bacterial infections.